WO2025031481 - RXFP1 RECEPTOR MODULATOR AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/031481
Publication Date
13.02.2025
International Application No.
PCT/CN2024/111004
International Filing Date
09.08.2024
Title **
[English]
RXFP1 RECEPTOR MODULATOR AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
[French]
MODULATEUR DU RÉCEPTEUR RXFP1 ET SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE
[Chinese]
一种RXFP1受体调节剂及其制备方法和医药用途
Applicants **
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
Inventors
WU, Junjun
LU, Yinsuo
JIA, Shuanglong
XIAO, Ying
WANG, Zongtao
DUAN, Zhenfang
ZOU, Junlong
Priority Data
202311015569.0
10.08.2023
CN
202311206019.7
18.09.2023
CN
202311372925.4
20.10.2023
CN
202410275924.6
11.03.2024
CN
202410354375.1
25.03.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2075 | |
| EPO | Filing, Examination, Granting | 12477 | |
| Japan | Filing, Examination, Granting | 2186 | |
| South Korea | Filing, Examination, Granting | 2335 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
23,813
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are a compound as shown in formula (I) that can be used as an RXFP1 receptor modulator, a preparation method therefor and the pharmaceutical use thereof. The compound has good RXFP1 receptor agonistic activity and can be used for treating heart failure.[French]
L'invention concerne un composé tel que représenté dans la formule (I) qui peut être utilisé en tant que modulateur du récepteur RXFP1, son procédé de préparation et son utilisation pharmaceutique. Le composé a une bonne activité agoniste du récepteur RXFP1 et peut être utilisé pour traiter une insuffisance cardiaque.[Chinese]
提供一种式（I）所示的可作为RXFP1受体调节剂的化合物及其制备方法和医药用途，所述化合物具有很好的RXFP1受体激动活性，可用于治疗心力衰竭。